Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06520189
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-20
Brief Title:
Value of F-18 FDG PETCT for the Prediction of EGFR Mutation in Lung Cancer Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Value of F-18 FDG PETCT for the Prediction of EGFR Mutation in Lung Cancer Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To detect value of F-18FDG PETCT as a non-invasive method for the prediction of EGFR mutations in lung cancer patients
Detailed Description:
Globally lung cancer cases and deaths are rising In 2018 GLOBOCAN estimated 209 million new cases 116 of total cancer cases and 176 million deaths 184 of total cancer deaths It is the most frequent cancer and cause of cancer death in men
Epidermal growth factor receptor EGFR mutations are the second most common oncogenic driver event in non-small cell lung cancer NSCLC and classical activating mutations are well defined as strong predictors for good clinical response to EGFR tyrosine kinase inhibitors EGFRi
Over the last decade the introduction of tyrosine-kinase inhibitors TKIs has showed a remarkable paradigm shift in the treatment of non-small cell lung cancer NSCLC However genetic testing is sometimes unavailable
Data from previous studies that have investigated the value of F-18 FDG PETCT for predicting EGFR status are conflicting
Epidermal growth factor receptor EGFR mutations are the second most common oncogenic driver event in non-small cell lung cancer NSCLC and classical activating mutations are well defined as strong predictors for good clinical response to EGFR tyrosine kinase inhibitors EGFRi
Over the last decade the introduction of tyrosine-kinase inhibitors TKIs has showed a remarkable paradigm shift in the treatment of non-small cell lung cancer NSCLC However genetic testing is sometimes unavailable
Data from previous studies that have investigated the value of F-18 FDG PETCT for predicting EGFR status are conflicting
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None